CA1284152C - 1'-ethoxycarbonyloxyethyl ester of valproic acid, its preparation and pharmaceutical compositions containing it - Google Patents
1'-ethoxycarbonyloxyethyl ester of valproic acid, its preparation and pharmaceutical compositions containing itInfo
- Publication number
- CA1284152C CA1284152C CA000441017A CA441017A CA1284152C CA 1284152 C CA1284152 C CA 1284152C CA 000441017 A CA000441017 A CA 000441017A CA 441017 A CA441017 A CA 441017A CA 1284152 C CA1284152 C CA 1284152C
- Authority
- CA
- Canada
- Prior art keywords
- valproic acid
- ester
- vpa
- preparation
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 title claims abstract description 94
- 150000002148 esters Chemical class 0.000 title claims abstract description 39
- 229960000604 valproic acid Drugs 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 5
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 4
- RKRZYVQFKUXDEZ-UHFFFAOYSA-N 1-bromoethyl ethyl carbonate Chemical group CCOC(=O)OC(C)Br RKRZYVQFKUXDEZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000000651 prodrug Substances 0.000 description 12
- 229940002612 prodrug Drugs 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 239000001961 anticonvulsive agent Substances 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000003556 anti-epileptic effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 229940084026 sodium valproate Drugs 0.000 description 5
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 230000001037 epileptic effect Effects 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 229940093956 potassium carbonate Drugs 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- OMOMUFTZPTXCHP-UHFFFAOYSA-N valpromide Chemical compound CCCC(C(N)=O)CCC OMOMUFTZPTXCHP-UHFFFAOYSA-N 0.000 description 3
- VOLGAXAGEUPBDM-UHFFFAOYSA-N $l^{1}-oxidanylethane Chemical compound CC[O] VOLGAXAGEUPBDM-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- AJDIZQLSFPQPEY-UHFFFAOYSA-N 1,1,2-Trichlorotrifluoroethane Chemical compound FC(F)(Cl)C(F)(Cl)Cl AJDIZQLSFPQPEY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 229910019582 Cr V Inorganic materials 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940016681 dipropylacetamide Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 239000003196 psychodysleptic agent Substances 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C68/00—Preparation of esters of carbonic or haloformic acids
- C07C68/06—Preparation of esters of carbonic or haloformic acids from organic carbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/96—Esters of carbonic or haloformic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL67623A IL67623A (en) | 1983-01-05 | 1983-01-05 | 1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it |
| IL67623 | 1983-01-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1284152C true CA1284152C (en) | 1991-05-14 |
Family
ID=11053985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000441017A Expired - Lifetime CA1284152C (en) | 1983-01-05 | 1983-11-14 | 1'-ethoxycarbonyloxyethyl ester of valproic acid, its preparation and pharmaceutical compositions containing it |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4595695A (en:Method) |
| EP (1) | EP0114720B1 (en:Method) |
| JP (1) | JPS59128359A (en:Method) |
| AT (1) | ATE18197T1 (en:Method) |
| AU (1) | AU558445B2 (en:Method) |
| CA (1) | CA1284152C (en:Method) |
| DE (1) | DE3460035D1 (en:Method) |
| IL (1) | IL67623A (en:Method) |
| ZA (1) | ZA838666B (en:Method) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL67623A (en) * | 1983-01-05 | 1984-09-30 | Teva Pharma | 1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it |
| IT1190133B (it) * | 1986-06-19 | 1988-02-10 | Chiesi Farma Spa | Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche |
| CA2478093A1 (en) | 2002-02-28 | 2003-09-12 | A & D Bioscience, Inc. | Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof |
| WO2003079980A2 (en) * | 2002-03-19 | 2003-10-02 | A & D Bioscience, Inc. | Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof |
| WO2003086475A1 (en) * | 2002-04-12 | 2003-10-23 | A & D Bioscience, Inc. | Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof |
| WO2003094842A2 (en) * | 2002-05-07 | 2003-11-20 | A & D Bioscience, Inc. | Conjugates comprising central nervous system active drug |
| US20050215487A1 (en) * | 2002-06-27 | 2005-09-29 | Holick Michael F | Conjugates comprising an nsaid and a sugar and uses thereof |
| AU2003302472B2 (en) | 2002-11-22 | 2010-10-21 | The Johns Hopkins University | Target for therapy of cognitive impairment |
| EP1928807A4 (en) * | 2005-09-02 | 2011-05-04 | Picobella Llc | ONCOGENIC REGULATORS RNA FOR DIAGNOSIS AND THERAPY |
| US7459280B2 (en) * | 2006-02-27 | 2008-12-02 | Picobella, Llc | Methods for diagnosing and treating kidney cancer |
| US7763650B2 (en) * | 2006-03-15 | 2010-07-27 | Medipharma S.A. | Pharmaceutical compound and method |
| US20080267977A1 (en) * | 2007-04-26 | 2008-10-30 | Friedrich-Alexander University Of Erlangen-Nuremberg | Combined immunological agent and sensitizing agent for the treatment of cancer |
| CA2740610C (en) * | 2008-10-16 | 2020-01-07 | The Johns Hopkins University | Synaptic vesicle protein 2a inhibitors for treating age-related cognitive impairment |
| CN102905532A (zh) * | 2010-02-09 | 2013-01-30 | 约翰斯.霍普金斯大学 | 用于改善认知功能的方法和组合物 |
| CN104797568A (zh) * | 2012-05-08 | 2015-07-22 | 塞利克斯比奥私人有限公司 | 用于治疗神经障碍的组合物和方法 |
| HK1215170A1 (zh) | 2012-11-14 | 2016-08-19 | The Johns Hopkins University | 治療精神分裂症的方法和組合物 |
| CA2904767C (en) | 2013-03-15 | 2022-06-21 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| EA034167B8 (ru) | 2015-05-22 | 2021-04-27 | Эйджинбайо, Инк. | Фармацевтические композиции леветирацетама пролонгированного высвобождения |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2442M (fr) * | 1962-10-17 | 1964-04-06 | Henry Eugene | L'acide dipropylacétique et ses dérivés en tant que nouveuax médicaments dépresseurs du systeme nerveux central. |
| US3646201A (en) * | 1969-07-31 | 1972-02-29 | Liggett & Myers Inc | Salicylate carbonate compounds |
| GB1598568A (en) * | 1977-04-19 | 1981-09-23 | Glaxo Lab Ltd | Esters of(6r,7r)-3-carbamoyloxymethyl-7-((z)-2-(fur-2-yl)-2-methoxyiminoacetamido)-ceph-3-em-4-carboxylic acid |
| DE3262698D1 (en) * | 1981-11-17 | 1985-04-25 | Kabivitrum Ab | Antifibrinolytically active compounds |
| US4542158A (en) * | 1981-12-21 | 1985-09-17 | Merck & Co., Inc. | Prodrug esters of diflunisal and related compounds |
| NZ202721A (en) * | 1981-12-21 | 1985-12-13 | Merck & Co Inc | Diflunisal derivatives and pharmaceutical compositions |
| US4426391A (en) * | 1982-09-15 | 1984-01-17 | Merck & Co., Inc. | [(Alkoxycarbonyl)oxy]alkyl esters of methyldopa |
| IL67445A (en) * | 1982-12-09 | 1985-11-29 | Teva Pharma | Ethoxycarbonyloxy ethyl esters of non-steroidal anti-inflammatory carboxylic acids |
| IL67623A (en) * | 1983-01-05 | 1984-09-30 | Teva Pharma | 1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it |
-
1983
- 1983-01-05 IL IL67623A patent/IL67623A/xx unknown
- 1983-11-14 CA CA000441017A patent/CA1284152C/en not_active Expired - Lifetime
- 1983-11-16 US US06/552,336 patent/US4595695A/en not_active Expired - Fee Related
- 1983-11-16 AU AU21421/83A patent/AU558445B2/en not_active Ceased
- 1983-11-21 ZA ZA838666A patent/ZA838666B/xx unknown
- 1983-12-20 JP JP58238999A patent/JPS59128359A/ja active Granted
-
1984
- 1984-01-05 DE DE8484300049T patent/DE3460035D1/de not_active Expired
- 1984-01-05 EP EP84300049A patent/EP0114720B1/en not_active Expired
- 1984-01-05 AT AT84300049T patent/ATE18197T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0114720B1 (en) | 1986-02-26 |
| ZA838666B (en) | 1984-07-25 |
| IL67623A0 (en) | 1983-05-15 |
| AU558445B2 (en) | 1987-01-29 |
| US4595695A (en) | 1986-06-17 |
| EP0114720A1 (en) | 1984-08-01 |
| IL67623A (en) | 1984-09-30 |
| AU2142183A (en) | 1984-07-12 |
| ATE18197T1 (de) | 1986-03-15 |
| JPS59128359A (ja) | 1984-07-24 |
| DE3460035D1 (en) | 1986-04-03 |
| JPS6229423B2 (en:Method) | 1987-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1284152C (en) | 1'-ethoxycarbonyloxyethyl ester of valproic acid, its preparation and pharmaceutical compositions containing it | |
| EP0112130B1 (en) | Ethoxycarbonyloxy ethyl esters of non-steroidal anti-inflammatory carboxylic acids, their preparation and use | |
| EP0670825B1 (en) | Nitric esters having a pharmacological activity and process for their preparation | |
| JPS6315256B2 (en:Method) | ||
| FR2517302A1 (fr) | Esters et amides de 13 14-bisdehydroprostaglandines | |
| EP0061386B1 (fr) | Acides ((2-oxo-3-tétrahydrothiénylcarbamoyl)-alkylthio) acétiques, leurs sels et leurs esters, leur procédé de préparation et les compositions pharmaceutiques en contenant | |
| US5945407A (en) | Methods and compositions using butyrate esters of threitol | |
| US3853952A (en) | 2-ethynylcyclopropane compounds and process for the preparation thereof | |
| US4325974A (en) | β, γ-Dihydropolyprenyl alcohol and hypotensive pharmaceutical composition containing same | |
| EP1527063A1 (en) | The 9, 11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma | |
| US4950818A (en) | Method for treating ulcer | |
| FR2580632A1 (fr) | Ethers cyclopentiliques, leur preparation et formulation pharmaceutiques les contenant | |
| IE832094L (en) | Benzamido derivatives. | |
| LU83183A1 (fr) | Nouvelle classe de derives acyles de carnitine,leur procede de preparation et leur utilisation therapeutique | |
| US4442124A (en) | Valproic acid ester with antiepileptic and anticonvulsant activity and pharmaceutical compositions therefrom | |
| US5196567A (en) | Biphenylylpropionic acid derivative, process for preparing the same and pharmaceutical composition containing the same | |
| EP0009306B1 (en) | Anti-arthritic hydroxyacetic acid derivatives, pharmaceutical compositions thereof, and processes for their manufacture | |
| FI72973B (fi) | Foerfarande foer framstaellning av farmakologiskt aktiva 2-oxabicyklo/3.3.0/oktanderivat. | |
| US4361572A (en) | Tetrahydronicotinamide derivative, pharmaceutical compositions and use | |
| AU718983B2 (en) | Butyrate prodrugs of lactic acid | |
| JPS6226249A (ja) | 光学活性乳酸エステルの精製方法 | |
| US4080474A (en) | Hypolipidaemic compositions | |
| NO861903L (no) | Farmasoeytiske preparater av "prodrug" typen, fremgangsmaate for fremstilling derav og fremgangsmaate for fremstilling av de som "prodrug" fungerende forbindelsene. | |
| ES2204066T3 (es) | Ciclopropilatos de alfa-tocoferol, los nuevos derivados de vitamina e, y metodo para producirlos. | |
| KR890000376B1 (ko) | 신규한 나프록센의 알칸올 에스테르 유도체의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |